NCT01397799View on ClinicalTrials.gov

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

KX2-391

Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.

Trial Locations (3)

10065

Weill Cornell Medical College, New York

14263

Roswell Park Cancer Institute, Buffalo

19107

Thomas Jefferson University, Philadelphia

Sponsors
All Listed Sponsors
lead

Kinex Pharmaceuticals Inc.

INDUSTRY